Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2

Gene Therapy

Volumn 3, Issue 12, 1996, Pages 1104-1112

  Quintin Colonna, F ^a   Devauchelle, P ^b   Fradelizi, D ^c   Mourot, B ^e   Faure, T ^e   Kourilsky, P ^d   Roth, C ^d   Mehtali, M ^e  

^a ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^b Centre Radiotherapie Scanner   (France)

^c Hôpital Cochin ^*  (France)

^d INSTITUT PASTEUR   (France)

^e TRANSGENE S A   (France)

Author keywords

Cancer gene therapy; Cats; Dogs; Il 2; Spontaneous tumors; Xenogeneic cell

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CAT; CONTROLLED STUDY; DOG; FEMALE; FIBROSARCOMA; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HISTOINCOMPATIBILITY; IMMUNE RESPONSE; INTRATUMORAL DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SAFETY; SURVIVAL TIME; VERO CELL;

ANIMALS; CAT DISEASES; CATS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COMBINED MODALITY THERAPY; DOG DISEASES; DOGS; FEMALE; FIBROSARCOMA; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HISTOCOMPATIBILITY; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; RATS; RATS, SPRAGUE-DAWLEY; RECURRENCE; VERO CELLS;

EID: 0030472123     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Foa R, Guarini A, Gansbacher B. IL-2 treatment for cancer: from biology to gene therapy. Br J Cancer 1992; 66: 992-998.
2. Pardoll DM Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-115.
3. Gansbacher B, Rosenthal F, Zier K. Retroviral vector-mediated cytokine gene transfer into tumor cells. Cancer Inv 1993; 11: 345-354.
4. Schmidt-Wolf G, Schmidt-Wolf ICH. Cytokines and clinical gene therapy. Eur J Immunol 1995; 25: 1137-1140.
5. Whartenby KA et al. Gene-modified cells for the treatment of cancer. Pharmacol Ther 1995; 66: 175-190.
6. Tahara H, Lotze MT. Gene therapy for adult cancer: advances in immunologic approaches using cytokines. In: Chang P (ed). Somatic Gene Therapy. CRC Press: Boca Raton, 1995, pp 263-285.
7. Dalgleish AG. The role of IL-2 in gene therapy. Gene Therapy 1994; 1: 83-87.
8. List of clinical protocols in Cancer Gene Therapy. Canc Gene Ther 1995; 2: 225-234.
9. Cordier L et al. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Therapy 1995; 2: 16-21.
10. Addison CL et al. Intratumoral injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522-8526.
11. Hurford RK, Dranoff G, Mulligan RC, Tepper RI. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genet 1995; 10: 430-435.
12. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
13. Qin HX, Chatterjee SK. Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine. Gene Therapy 1996; 3. 59-66.
14. Roth C et al. Inhibition of tumor growth by histoincompatible cells expressing interieukin-2. Int Immunol 1992; 4: 1429-1436.
15. Cressent M et al. Interleukin-2 and interleukin-4 display potent antitumour activity on rat medullary thyroid carcinoma cells. Eur J Cancer 1995; 311: 2379-2384.
16. Bostock DE, Dye MT. Prognosis after surgical excision of fibrosarcomas in cats. J Am Vet Med Assoc 1979; 175: 727-728.
17. Theilen GH, Madewell BR. Feline fibrosarcoma. In: Theilen GH, Madewell BR (eds). Veterinary Cancer Medicine, 2nd edn. Lea and Febiger: Philadelphia, 1987, pp 382-391.
18. Bostock DE. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 1986; 142: 1-19.
19. Hahn KA, DeNicola DB, Richardson RC, Hahn EA. Canine oral malignant melanoma: prognostic utility of an alternative staging system J Small Anim Pract 1994; 35: 251-256.
20. Kosovsky JK, Matthiesen DT, Marretta SM, Patnaik AK. Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs. Vet Surg 1991; 20: 397-401.
21. Harvey HJ et al. Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc 1981; 178: 580-582.
22. Simuzu B, Terasima T (eds) VERO Cells: Origin, Properties and Biomedical Applications. The Twenty-Fifth Anniversary of the Establishment. Department of Microbiology, School of Medicine, Chiba University Chiba, 1987.
23. Hendrick MJ et al. Comparison of fibrosarcomas that developed at vaccination sites and at non vaccination sites in cats: 239 cases (1991-1992). J Am Vet Med Assoc 1994; 205: 1425-1429.
24. Kass PH et al. Epidemiological evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. J Am Vet Med Assoc 1993; 203: 396-405.
25. Mir LM et al. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J Immunother 1995; 17: 30-38.
26. Belehradek M et al. Electrochemotherapy, a new antitumor treatment. Cancer 1993; 72: 3694-3700.
27. Lam JS et al. Effect of local tumor irradiation and interleukin-2 therapy in different murine tumors. J Immunother 1995; 18: 28-34.
28. Whitley EM, Bird AC, Zucker KE. Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines. Anticancer Res 1995; 15: 923-929.
29. Rosenthal FM et al. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNA. Blood 1994; 83: 1289-1298.
30. Schmidt WS et al. Cancer vaccines: the interleukin-2 dosage effect. Proc Natl Acad Sci USA 1995; 92: 4711-4714.
31. Konrad MW et al. Pharmacokinetics of recombinant interleukin-2 in humans. Cancer Res 1990; 50: 2009-2017.
32. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin-2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 1988; 18: 97-104.
33. Boshart M et al. A very strong enhancer is located upstream of an immediate - early gene of human cytomegalovirus. Cell 1985; 41: 521-530.
34. Brearhach R, Harris BA. Plasmids for the cloning of full-length double-stranded cDNAs under the control of the SV40 early or late gene promoter. Nucleic Acids Res 1983; 11: 7119-7136.
35. Vara JA, Portela J, Jimenez A. Expression in mammalian cells of a gene from Streptomyces alboniger conferring puromycin resistance. Nucleic Acids Res 1986; 14: 4617-4624.
36. Horowitz M, Cepko CL, Sharp P. SV40 as a vector for cloning eukaryotic sequences that affect post-transcriptional processing. In Gluzman Y (ed). Eukaryotic Viral Vectors. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1986, pp 47-67.
37. Luftalla G, Blanc H, Bertolotti R. Shuttling of integrated vectors from mammalian cells to E. coli is mediated in head-to-tail multimeric inserts. Som Cell Mol Gen 1985; 11: 223-238.
38. Meulien P et al. A new recombinant procoagulant protein derived from the cDNA encoding human factor VIII. Protein Eng 1988; 2: 301-306.
39. Graham FL, Van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
40. Hammerling L, Henningsson AC, Sjodin L. Development and validation of a bioassay for interleukin-2. J Pharmac Biomed Anal 1992; 10: 547-553.